Genfit SA, of Lille, France, said the first patient has been enrolled in a phase IIa trial evaluating elafibranor in primary biliary cholangitis (PBC). The three-arm (80 mg, 120 mg and placebo) study will evaluate the efficacy and safety of the compound in adult patients with PBC and inadequate response to ursodeoxycholic acid. It will enroll 45 patients (15 patients per arm) who will receive 12 weeks of treatment. The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase, based on relative change from baseline to end of treatment compared to placebo.